ÐÓ°ÉÂÛ̳

Skip to main content
Quest Diagnostics

Cerebrospinal Fluid A¦Â42, Total Tau, and Phosphorylated Tau in the Evaluation of Alzheimer¡¯s Dementia: Experience From a Commercial Reference Laboratory

4th edition of Innovations and State of the Art in Alzheimer's & Dementia

ISAD 2023

Barcelona, Spain, Sep 13-14 , 2023

Oral presentation:?

Authors:?Batish SD, Haji-Sheikhi F, Kare AR, Datta V, Meservey M, Radcliff J

Specialty:?Neurology

Related content

On-Demand Webinar
Assessing Alzheimer's Disease Risk in Primary Care Settings
Audio Podcast
Alzheimer¡¯s disease: A new generation of screenings and therapies on the horizon
On-Demand Webinar
The Emerging Role of Blood-based Biomarkers in Alzheimer's Disease
Conference Presentation
The AlzMatch Study: remote plasma acquisition to pre-screen for preclinical Alzheimer's disease trials
Conference Presentation
Cerebrospinal Fluid A¦Â42, Total Tau, and Phosphorylated Tau in the Evaluation of Alzheimer¡¯s Dementia: Experience From a Commercial Reference Laboratory

Our company

Quest? is the brand name used for services offered by ÐÓ°ÉÂÛ̳ and its affiliated companies. ÐÓ°ÉÂÛ̳ and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.? Other affiliates operated under the Quest? brand, such as Quest Consumer Inc., do not provide HIPAA-covered services.?

?

Quest?, Quest Diagnostics?, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks¡ª? and ?¡ªare the property of their respective owners. ? 2025 ÐÓ°ÉÂÛ̳. All rights reserved. Image content features models and is intended for illustrative purposes only.